Hypothesis: Metabolic Priming via AMPK Activation Creates a Vulnerable Window for Senolytic Action

Core Idea: Senescent cells exhibit fluctuating metabolic states; transient AMPK activation (e.g., through exercise, fasting, or pharmacologic agents like AICAR) lowers intracellular ATP, increases NAD+/NADH ratio, and transiently suppresses BCL-2 family anti-apoptotic proteins, rendering senescent cells more susceptible to senolytic-induced apoptosis. Synchronizing senolytic dosing to these AMPK-high phases should increase clearance efficacy while allowing lower drug exposure, reducing off-target toxicity.

Mechanistic Rationale:

• AMPK activation phosphorylates and inhibits mTORC1, shifting cells toward autophagy and reducing SASP secretion [mTOR inhibition and AMPK activation modulate senescent cell survival and inflammatory SASP]
• AMPK-driven NAD+ biosynthesis via NAMPT elevates SIRT1 activity, which deacetylates p53 and FOXO transcription factors, promoting expression of pro-apoptotic BH3-only proteins (e.g., PUMA, NOXA) [NAD+ restoration reconfigures metabolism and rejuvenates senescent human mesenchymal stem cells]
• Transient AMPK activation also decreases mitochondrial membrane potential, priming the intrinsic apoptosis pathway; senolytics such as dasatinib + quercetin rely on inhibition of SRC family kinases and BCL-XL/Bcl-2 to trigger caspase activation [Senolytics improve physical function and can increase lifespan by 36% in old mice]
• Therefore, a brief AMPK "hit" creates a synthetic lethal context where lower senolytic concentrations achieve equivalent apoptosis, widening the therapeutic index.

Testable Predictions:

1. In human senocyte cultures (e.g., irradiated IMR-90 fibroblasts), a 2-hour pretreatment with AICAR (AMPK agonist) followed by dasatinib + quercetin will increase Annexin V+/PI+ cells by >=2-fold compared to senolytic alone, while caspase-3 activity rises correspondingly.
2. In vivo, old mice receiving intermittent fasting (16 h fast) 30 min before each dasatinib + quercetin dose (2 days on/13 off) will show greater reduction of p16^INK4a^-positive cells in liver and adipose tissue after 4 weeks, with unchanged platelet counts (navitoclax-like toxicity control).
3. Pharmacodynamic markers: AMPK-high state (p-AMPK Thr172) in peripheral blood mononuclear cells will correlate inversely with circulating SASP factors (IL-6, IL-8) post-treatment; mice lacking AMPKalpha1 in hematopoietic cells will not exhibit the enhanced senolytic effect.
4. A clinical pilot (SToMP-AD-like) adding a 12-hour fast before each dasatinib + quercetin cycle will achieve comparable cognitive/functional endpoints at half the drug dose, reducing adverse events.

Falsifiability: If AMPK activation does not augment senolytic-induced apoptosis in vitro, or if fasting-timed dosing fails to improve tissue senescent cell burden or toxicity profile in vivo, the hypothesis is refuted.

Implementation: Use crossover design in mice, measure p-AMPK, NAD+/NADH, SASP, and senocyte burden via flow cytometry for p16^INK4a^ and SA-beta-gal. For humans, leverage existing SToMP-AD infrastructure with added fasting instruction and pharmacokinetic monitoring.

Broader Impact: Aligning senolytic delivery with endogenous metabolic rhythms could translate intermittent dosing from empirical to mechanistically optimized, addressing toxicity, specificity, and tissue-specific efficacy gaps highlighted in current trials.